Choi Younak, Keam Bhumsuk, Kim Tae Min, Lee Se-Hoon, Kim Dong-Wan, Heo Dae Seog
Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2015 Oct;47(4):555-63. doi: 10.4143/crt.2014.200. Epub 2015 Feb 16.
The purpose of this study was to investigate and compare cancer treatment near the end-of-life (EOL) over a 10-year period.
Patients with advanced solid cancer at Seoul National University Hospital who received palliative chemotherapy and had died were enrolled. We categorized the consecutive patients according to two time periods: 2002 (n=57) and 2012 (n=206). Aggressiveness of cancer treatment near the EOL was evaluated.
The median patient age was 62, and 65.4% of patients (n=172) were male. Time from the last chemotherapy to death (TCD) was found to have been significantly shortened, from 66.0 days to 34.0 days during 10 years (p < 0.001); 17% of patients received molecular targeted agents as the last chemotherapy regimen in 2012. The proportion of patients who received intensive care unit care within the last month increased from 1.8% in 2002 to 19.9% in 2012 (p < 0.001), and emergency room visits within the last month also increased from 22.8% to 74.8% (p < 0.001). Although hospice referral increased from 9.1% to 37.4% (p < 0.001), timing of referral was delayed from median 53 days to 8 days before death (p=0.004). Use of targeted agents as the last chemotherapy for over-two-regimen users was associated with shortened TCD (hazard ratio, 2.564; p=0.002).
Cancer treatment near the EOL became more aggressive over 10 years.
本研究旨在调查和比较10年间临终前的癌症治疗情况。
纳入首尔国立大学医院接受姑息化疗且已死亡的晚期实体癌患者。我们将连续的患者按两个时间段分类:2002年(n = 57)和2012年(n = 206)。评估临终前癌症治疗的积极程度。
患者中位年龄为62岁,65.4%的患者(n = 172)为男性。发现从最后一次化疗到死亡的时间(TCD)在10年间显著缩短,从66.0天缩短至34.0天(p < 0.001);2012年17%的患者接受分子靶向药物作为最后化疗方案。在最后一个月内接受重症监护病房护理的患者比例从2002年的1.8%增至2012年的19.9%(p < 0.001),最后一个月内急诊就诊的患者比例也从22.8%增至74.8%(p < 0.001)。尽管临终关怀转诊从9.1%增至37.4%(p < 0.001),但转诊时间从中位死亡前53天延迟至8天(p = 0.004)。对于接受过两种以上化疗方案的患者,使用靶向药物作为最后化疗与TCD缩短相关(风险比,2.564;p = 0.002)。
在10年期间,临终前的癌症治疗变得更加积极。